# MBG453 in Lower Risk MDS

> **NCT04823624** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 10 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** MBG453

## Key facts

- **NCT ID:** NCT04823624
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-27
- **Primary completion:** 2024-11-12
- **Final completion:** 2025-11-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The trial closed early due to changes in support for the study drug.
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04823624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04823624, "MBG453 in Lower Risk MDS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04823624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*